ID   CTBP1_HUMAN             Reviewed;         440 AA.
AC   Q13363; Q4W5N3; Q7Z2Q5;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1999, sequence version 2.
DT   10-MAY-2017, entry version 189.
DE   RecName: Full=C-terminal-binding protein 1;
DE            Short=CtBP1;
DE            EC=1.1.1.-;
GN   Name=CTBP1; Synonyms=CTBP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 98-108,
RP   AND INTERACTION WITH RBBP8 AND ADENOVIRUS E1A.
RC   TISSUE=B-cell, and Cervix carcinoma;
RX   PubMed=7479821; DOI=10.1073/pnas.92.23.10467;
RA   Schaeper U., Boyd J.M., Verma S., Uhlmann E., Subramanian T.,
RA   Chinnadurai G.;
RT   "Molecular cloning and characterization of a cellular phosphoprotein
RT   that interacts with a conserved C-terminal domain of adenovirus E1A
RT   involved in negative modulation of oncogenic transformation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:10467-10471(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SEQUENCE REVISION, AND
RP   FUNCTION.
RX   PubMed=9858600; DOI=10.1128/MCB.19.1.777;
RA   Sewalt R.G.A.B., Gunster M.J., van der Vlag J., Satijn D.P.E.,
RA   Otte A.P.;
RT   "C-terminal binding protein is a transcriptional repressor that
RT   interacts with a specific class of vertebrate polycomb proteins.";
RL   Mol. Cell. Biol. 19:777-787(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   INTERACTION WITH ADENOVIRUS E1A, AND PHOSPHORYLATION.
RX   PubMed=8440238;
RA   Boyd J.M., Subramanian T., Schaeper U., la Regina M., Bayley S.,
RA   Chinnadurai G.;
RT   "A region in the C-terminus of adenovirus 2/5 E1a protein is required
RT   for association with a cellular phosphoprotein and important for the
RT   negative modulation of T24-ras mediated transformation, tumorigenesis
RT   and metastasis.";
RL   EMBO J. 12:469-478(1993).
RN   [7]
RP   INTERACTION WITH MECOM.
RX   PubMed=11568182; DOI=10.1074/jbc.M106733200;
RA   Chakraborty S., Senyuk V., Sitailo S., Chi Y., Nucifora G.;
RT   "Interaction of EVI1 with cAMP-responsive element-binding protein-
RT   binding protein (CBP) and p300/CBP-associated factor (P/CAF) results
RT   in reversible acetylation of EVI1 and in co-localization in nuclear
RT   speckles.";
RL   J. Biol. Chem. 276:44936-44943(2001).
RN   [8]
RP   INTERACTION WITH EBV EBNA6.
RX   PubMed=11462050; DOI=10.1128/JVI.75.16.7749-7755.2001;
RA   Touitou R., Hickabottom M., Parker G., Crook T., Allday M.J.;
RT   "Physical and functional interactions between the corepressor CtBP and
RT   the Epstein-Barr virus nuclear antigen EBNA3C.";
RL   J. Virol. 75:7749-7755(2001).
RN   [9]
RP   INTERACTION WITH NRIP1.
RX   PubMed=11509661; DOI=10.1128/MCB.21.18.6181-6188.2001;
RA   Vo N., Fjeld C., Goodman R.H.;
RT   "Acetylation of nuclear hormone receptor-interacting protein RIP140
RT   regulates binding of the transcriptional corepressor CtBP.";
RL   Mol. Cell. Biol. 21:6181-6188(2001).
RN   [10]
RP   INTERACTION WITH EBV EBNA3.
RX   PubMed=12372828; DOI=10.1074/jbc.M208116200;
RA   Hickabottom M., Parker G.A., Freemont P., Crook T., Allday M.J.;
RT   "Two nonconsensus sites in the Epstein-Barr virus oncoprotein EBNA3A
RT   cooperate to bind the co-repressor carboxyl-terminal-binding protein
RT   (CtBP).";
RL   J. Biol. Chem. 277:47197-47204(2002).
RN   [11]
RP   SUMOYLATION AT LYS-428, AND SUBCELLULAR LOCATION.
RX   PubMed=12679040; DOI=10.1016/S0092-8674(03)00159-4;
RA   Kagey M.H., Melhuish T.A., Wotton D.;
RT   "The polycomb protein Pc2 is a SUMO E3.";
RL   Cell 113:127-137(2003).
RN   [12]
RP   INTERACTION WITH HIPK2, PHOSPHORYLATION AT SER-422, AND MUTAGENESIS OF
RP   SER-422.
RX   PubMed=14567915; DOI=10.1016/S0092-8674(03)00802-X;
RA   Zhang Q., Yoshimatsu Y., Hildebrand J., Frisch S.M., Goodman R.H.;
RT   "Homeodomain interacting protein kinase 2 promotes apoptosis by
RT   downregulating the transcriptional corepressor CtBP.";
RL   Cell 115:177-186(2003).
RN   [13]
RP   FUNCTION IN TRANSCRIPTIONAL REPRESSION, AND INTERACTION WITH PNN.
RX   PubMed=15542832; DOI=10.1128/MCB.24.23.10223-10235.2004;
RA   Alpatov R., Munguba G.C., Caton P., Joo J.H., Shi Y., Shi Y.,
RA   Hunt M.E., Sugrue S.P.;
RT   "Nuclear speckle-associated protein Pnn/DRS binds to the
RT   transcriptional corepressor CtBP and relieves CtBP-mediated repression
RT   of the E-cadherin gene.";
RL   Mol. Cell. Biol. 24:10223-10235(2004).
RN   [14]
RP   INTERACTION WITH NRIP1.
RX   PubMed=15060175; DOI=10.1093/nar/gkh524;
RA   Castet A., Boulahtouf A., Versini G., Bonnet S., Augereau P.,
RA   Vignon F., Khochbin S., Jalaguier S., Cavailles V.;
RT   "Multiple domains of the receptor-interacting protein 140 contribute
RT   to transcription inhibition.";
RL   Nucleic Acids Res. 32:1957-1966(2004).
RN   [15]
RP   INTERACTION WITH ZFHX1B.
RX   PubMed=16061479; DOI=10.1074/jbc.M504477200;
RA   Long J., Zuo D., Park M.;
RT   "Pc2-mediated sumoylation of Smad-interacting protein 1 attenuates
RT   transcriptional repression of E-cadherin.";
RL   J. Biol. Chem. 280:35477-35489(2005).
RN   [16]
RP   INTERACTION WITH MECOM.
RX   PubMed=15897867; DOI=10.1038/sj.onc.1208754;
RA   Nitta E., Izutsu K., Yamaguchi Y., Imai Y., Ogawa S., Chiba S.,
RA   Kurokawa M., Hirai H.;
RT   "Oligomerization of Evi-1 regulated by the PR domain contributes to
RT   recruitment of corepressor CtBP.";
RL   Oncogene 24:6165-6173(2005).
RN   [17]
RP   INTERACTION WITH FOXP1.
RX   PubMed=16609867; DOI=10.1007/s00427-006-0073-8;
RA   Schoen C., Wochnik A., Roessner A., Donow C., Knoechel W.;
RT   "The FoxP subclass in Xenopus laevis development.";
RL   Dev. Genes Evol. 216:641-646(2006).
RN   [18]
RP   INTERACTION WITH WIZ.
RX   PubMed=16702210; DOI=10.1074/jbc.M603087200;
RA   Ueda J., Tachibana M., Ikura T., Shinkai Y.;
RT   "Zinc finger protein Wiz links G9a/GLP histone methyltransferases to
RT   the co-repressor molecule CtBP.";
RL   J. Biol. Chem. 281:20120-20128(2006).
RN   [19]
RP   INTERACTION WITH ZNF366.
RX   PubMed=16393996; DOI=10.4049/jimmunol.176.2.1081;
RA   Triantis V., Trancikova D.E., Looman M.W., Hartgers F.C.,
RA   Janssen R.A., Adema G.J.;
RT   "Identification and characterization of DC-SCRIPT, a novel dendritic
RT   cell-expressed member of the zinc finger family of transcriptional
RT   regulators.";
RL   J. Immunol. 176:1081-1089(2006).
RN   [20]
RP   INTERACTION WITH ZNF366.
RX   PubMed=17085477; DOI=10.1093/nar/gkl875;
RA   Lopez-Garcia J., Periyasamy M., Thomas R.S., Christian M., Leao M.,
RA   Jat P., Kindle K.B., Heery D.M., Parker M.G., Buluwela L.,
RA   Kamalati T., Ali S.;
RT   "ZNF366 is an estrogen receptor corepressor that acts through CtBP and
RT   histone deacetylases.";
RL   Nucleic Acids Res. 34:6126-6136(2006).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-300, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [22]
RP   FUNCTION AS COREPRESSOR, INTERACTION WITH BCL6, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=18212045; DOI=10.1128/MCB.01400-07;
RA   Mendez L.M., Polo J.M., Yu J.J., Krupski M., Ding B.B., Melnick A.,
RA   Ye B.H.;
RT   "CtBP is an essential corepressor for BCL6 autoregulation.";
RL   Mol. Cell. Biol. 28:2175-2186(2008).
RN   [23]
RP   FUNCTION, AND INTERACTION WITH SATB1.
RX   PubMed=19103759; DOI=10.1128/MCB.00822-08;
RA   Purbey P.K., Singh S., Notani D., Kumar P.P., Limaye A.S., Galande S.;
RT   "Acetylation-dependent interaction of SATB1 and CtBP1 mediates
RT   transcriptional repression by SATB1.";
RL   Mol. Cell. Biol. 29:1321-1337(2009).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-300, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [26]
RP   INTERACTION WITH HADV5 E1A.
RX   PubMed=23747199; DOI=10.1016/j.virol.2013.05.018;
RA   Subramanian T., Zhao L.J., Chinnadurai G.;
RT   "Interaction of CtBP with adenovirus E1A suppresses immortalization of
RT   primary epithelial cells and enhances virus replication during
RT   productive infection.";
RL   Virology 443:313-320(2013).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [28]
RP   INTERACTION WITH MCRIP1.
RX   PubMed=25728771; DOI=10.1016/j.molcel.2015.01.023;
RA   Ichikawa K., Kubota Y., Nakamura T., Weng J.S., Tomida T., Saito H.,
RA   Takekawa M.;
RT   "MCRIP1, an ERK substrate, mediates ERK-induced gene silencing during
RT   epithelial-mesenchymal transition by regulating the co-repressor
RT   CtBP.";
RL   Mol. Cell 58:35-46(2015).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 28-353 IN COMPLEX WITH NAD,
RP   FUNCTION, COFACTOR, MUTAGENESIS OF CYS-134; ASN-138; ARG-141;
RP   141-ARG-ARG-142; LEU-150; ARG-163; ARG-171; GLY-181; GLY-183; ASP-204;
RP   ARG-266; ASP-290; GLU-295 AND HIS-315, AND DIMERIZATION.
RX   PubMed=12419229; DOI=10.1016/S1097-2765(02)00650-0;
RA   Kumar V., Carlson J.E., Ohgi K.A., Edwards T.A., Rose D.W.,
RA   Escalante C.R., Rosenfeld M.G., Aggarwal A.K.;
RT   "Transcription corepressor CtBP is an NAD(+)-regulated
RT   dehydrogenase.";
RL   Mol. Cell 10:857-869(2002).
CC   -!- FUNCTION: Corepressor targeting diverse transcription regulators
CC       such as GLIS2 or BCL6. Has dehydrogenase activity. Involved in
CC       controlling the equilibrium between tubular and stacked structures
CC       in the Golgi complex. Functions in brown adipose tissue (BAT)
CC       differentiation. {ECO:0000269|PubMed:12419229,
CC       ECO:0000269|PubMed:15542832, ECO:0000269|PubMed:18212045,
CC       ECO:0000269|PubMed:19103759, ECO:0000269|PubMed:9858600}.
CC   -!- COFACTOR:
CC       Name=NAD(+); Xref=ChEBI:CHEBI:57540;
CC         Evidence={ECO:0000269|PubMed:12419229};
CC       Note=NAD is required for efficient interaction with E1A. Cofactor
CC       binding induces a conformation change.
CC       {ECO:0000269|PubMed:12419229};
CC   -!- SUBUNIT: Homo- or heterodimer. Heterodimer with CTBP2. Interacts
CC       with PRDM16; the interaction represses white adipose tissue (WAT)-
CC       specific genes expression. Interacts with GLIS2, FOXP2, HDAC4,
CC       HDAC5, HDAC9 and ZNF217. Interacts with adenovirus E1A protein
CC       (via its C-terminus); the interaction disrupts the interaction of
CC       CTBP1 with RBBP8. Interacts with Epstein-Barr virus EBNA3 and
CC       EBNA6. Interacts with ELK3 (via its PXDLS motif). Interacts with
CC       RBBP8 (via its PXDLS motif); the interaction is disrupted by
CC       binding to adenovirus E1A. Interacts with FOXP1, HIPK2, PNN,
CC       NRIP1, MECOM, ZFHX1B and WIZ. Interacts with ZNF366 (via PXDLS
CC       motif) (PubMed:16393996, PubMed:17085477). Interaction with SATB1
CC       (non-acetylated form); the interaction stabilizes its attachment
CC       to DNA and promotes transcription repression. Interacts with BCL6;
CC       the interaction is required for BCL6 transcriptional
CC       autoinhibition and inhibition of some BCL6 target genes. Interacts
CC       with IKZF4 (By similarity). Interacts with human adenovirus 5 E1A
CC       protein; this interaction seems to potentiate viral replication
CC       (PubMed:23747199). Interacts with MCRIP1 (unphosphorylated form,
CC       via the PXDLS motif); competitively inhibiting CTBP-ZEB1
CC       interaction (PubMed:25728771). {ECO:0000250|UniProtKB:O88712,
CC       ECO:0000269|PubMed:11462050, ECO:0000269|PubMed:11509661,
CC       ECO:0000269|PubMed:11568182, ECO:0000269|PubMed:12372828,
CC       ECO:0000269|PubMed:12419229, ECO:0000269|PubMed:14567915,
CC       ECO:0000269|PubMed:15060175, ECO:0000269|PubMed:15542832,
CC       ECO:0000269|PubMed:15897867, ECO:0000269|PubMed:16061479,
CC       ECO:0000269|PubMed:16393996, ECO:0000269|PubMed:16609867,
CC       ECO:0000269|PubMed:16702210, ECO:0000269|PubMed:17085477,
CC       ECO:0000269|PubMed:18212045, ECO:0000269|PubMed:19103759,
CC       ECO:0000269|PubMed:23747199, ECO:0000269|PubMed:25728771,
CC       ECO:0000269|PubMed:7479821, ECO:0000269|PubMed:8440238}.
CC   -!- INTERACTION:
CC       Q9H6U6:BCAS3; NbExp=3; IntAct=EBI-10171858, EBI-6083685;
CC       P55273:CDKN2D; NbExp=3; IntAct=EBI-10171858, EBI-745859;
CC       Q76N32:CEP68; NbExp=3; IntAct=EBI-10171858, EBI-9051024;
CC       Q49AN0:CRY2; NbExp=3; IntAct=EBI-10171858, EBI-2212355;
CC       P56545:CTBP2; NbExp=3; IntAct=EBI-10171858, EBI-741533;
CC       Q8IY44:CTBP2; NbExp=3; IntAct=EBI-10171858, EBI-10171902;
CC       I6L9A0:DMRTB1; NbExp=3; IntAct=EBI-10171858, EBI-10178554;
CC       O15409:FOXP2; NbExp=5; IntAct=EBI-10171858, EBI-983612;
CC       Q9BXL5:HEMGN; NbExp=2; IntAct=EBI-908846, EBI-3916399;
CC       Q14526:HIC1; NbExp=4; IntAct=EBI-908846, EBI-2507362;
CC       P09067:HOXB5; NbExp=3; IntAct=EBI-10171858, EBI-3893317;
CC       Q13422:IKZF1; NbExp=3; IntAct=EBI-10171858, EBI-745305;
CC       Q13422-7:IKZF1; NbExp=4; IntAct=EBI-10171858, EBI-11522367;
CC       Q9Y4X4:KLF12; NbExp=5; IntAct=EBI-10171858, EBI-750750;
CC       O43474:KLF4; NbExp=4; IntAct=EBI-908846, EBI-7232405;
CC       P45984:MAPK9; NbExp=3; IntAct=EBI-10171858, EBI-713568;
CC       O94818-2:NOL4; NbExp=3; IntAct=EBI-10171858, EBI-10190763;
CC       Q96MY1:NOL4L; NbExp=3; IntAct=EBI-10171858, EBI-6660790;
CC       Q9NQ66:PLCB1; NbExp=3; IntAct=EBI-10171858, EBI-3396023;
CC       Q13131:PRKAA1; NbExp=3; IntAct=EBI-10171858, EBI-1181405;
CC       Q9NYB0:TERF2IP; NbExp=2; IntAct=EBI-908846, EBI-750109;
CC       Q15583:TGIF1; NbExp=3; IntAct=EBI-10171858, EBI-714215;
CC       Q15583-2:TGIF1; NbExp=3; IntAct=EBI-10171858, EBI-12691451;
CC       Q96EK4:THAP11; NbExp=2; IntAct=EBI-908846, EBI-1790529;
CC       A1L0U7:TSHZ3; NbExp=3; IntAct=EBI-10171858, EBI-10171826;
CC       A2APF7:Zbp1 (xeno); NbExp=2; IntAct=EBI-908846, EBI-6115394;
CC       Q8N895:ZNF366; NbExp=5; IntAct=EBI-908846, EBI-2813661;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12679040}.
CC       Nucleus {ECO:0000269|PubMed:12679040}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q13363-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q13363-2; Sequence=VSP_043305;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in germinal center B-cells.
CC       {ECO:0000269|PubMed:18212045}.
CC   -!- PTM: The level of phosphorylation appears to be regulated during
CC       the cell cycle. Phosphorylation by HIPK2 on Ser-422 induces
CC       proteasomal degradation. {ECO:0000269|PubMed:14567915,
CC       ECO:0000269|PubMed:8440238}.
CC   -!- PTM: ADP-ribosylated; when cells are exposed to brefeldin A.
CC       {ECO:0000250}.
CC   -!- PTM: Sumoylation on Lys-428 is promoted by the E3 SUMO-protein
CC       ligase CBX4. {ECO:0000269|PubMed:12679040}.
CC   -!- SIMILARITY: Belongs to the D-isomer specific 2-hydroxyacid
CC       dehydrogenase family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U37408; AAC62822.1; -; mRNA.
DR   EMBL; AF091555; AAD14597.1; -; mRNA.
DR   EMBL; AC092535; AAY40989.1; -; Genomic_DNA.
DR   EMBL; CH471131; EAW82599.1; -; Genomic_DNA.
DR   EMBL; CH471131; EAW82600.1; -; Genomic_DNA.
DR   EMBL; CH471131; EAW82601.1; -; Genomic_DNA.
DR   EMBL; BC011655; AAH11655.1; -; mRNA.
DR   EMBL; BC053320; AAH53320.1; -; mRNA.
DR   CCDS; CCDS3348.1; -. [Q13363-1]
DR   CCDS; CCDS43203.1; -. [Q13363-2]
DR   RefSeq; NP_001012632.1; NM_001012614.1. [Q13363-2]
DR   RefSeq; NP_001319.1; NM_001328.2. [Q13363-1]
DR   RefSeq; XP_016863253.1; XM_017007764.1. [Q13363-2]
DR   RefSeq; XP_016863254.1; XM_017007765.1. [Q13363-2]
DR   RefSeq; XP_016863255.1; XM_017007766.1. [Q13363-2]
DR   RefSeq; XP_016863256.1; XM_017007767.1. [Q13363-2]
DR   UniGene; Hs.208597; -.
DR   PDB; 1MX3; X-ray; 1.95 A; A=28-353.
DR   PDB; 4LCE; X-ray; 2.38 A; A=28-353.
DR   PDB; 4U6Q; X-ray; 2.30 A; A=28-353.
DR   PDB; 4U6S; X-ray; 2.10 A; A=28-353.
DR   PDBsum; 1MX3; -.
DR   PDBsum; 4LCE; -.
DR   PDBsum; 4U6Q; -.
DR   PDBsum; 4U6S; -.
DR   ProteinModelPortal; Q13363; -.
DR   SMR; Q13363; -.
DR   BioGrid; 107869; 155.
DR   DIP; DIP-24245N; -.
DR   IntAct; Q13363; 54.
DR   MINT; MINT-94454; -.
DR   STRING; 9606.ENSP00000290921; -.
DR   BindingDB; Q13363; -.
DR   DrugBank; DB01942; Formic Acid.
DR   iPTMnet; Q13363; -.
DR   PhosphoSitePlus; Q13363; -.
DR   SwissPalm; Q13363; -.
DR   BioMuta; CTBP1; -.
DR   DMDM; 6014741; -.
DR   EPD; Q13363; -.
DR   PaxDb; Q13363; -.
DR   PeptideAtlas; Q13363; -.
DR   PRIDE; Q13363; -.
DR   DNASU; 1487; -.
DR   Ensembl; ENST00000290921; ENSP00000290921; ENSG00000159692. [Q13363-1]
DR   Ensembl; ENST00000382952; ENSP00000372411; ENSG00000159692. [Q13363-2]
DR   GeneID; 1487; -.
DR   KEGG; hsa:1487; -.
DR   UCSC; uc003gcu.2; human. [Q13363-1]
DR   CTD; 1487; -.
DR   DisGeNET; 1487; -.
DR   GeneCards; CTBP1; -.
DR   HGNC; HGNC:2494; CTBP1.
DR   HPA; CAB004217; -.
DR   HPA; HPA018987; -.
DR   HPA; HPA044971; -.
DR   MIM; 602618; gene.
DR   neXtProt; NX_Q13363; -.
DR   OpenTargets; ENSG00000159692; -.
DR   PharmGKB; PA26995; -.
DR   eggNOG; KOG0067; Eukaryota.
DR   eggNOG; COG0111; LUCA.
DR   GeneTree; ENSGT00530000063021; -.
DR   HOGENOM; HOG000136701; -.
DR   HOVERGEN; HBG001898; -.
DR   InParanoid; Q13363; -.
DR   KO; K04496; -.
DR   OMA; DRDHPSD; -.
DR   OrthoDB; EOG091G08GS; -.
DR   PhylomeDB; Q13363; -.
DR   TreeFam; TF313593; -.
DR   Reactome; R-HSA-3769402; Deactivation of the beta-catenin transactivating complex.
DR   Reactome; R-HSA-4641265; Repression of WNT target genes.
DR   Reactome; R-HSA-5339700; TCF7L2 mutants don't bind CTBP.
DR   SignaLink; Q13363; -.
DR   SIGNOR; Q13363; -.
DR   ChiTaRS; CTBP1; human.
DR   EvolutionaryTrace; Q13363; -.
DR   GeneWiki; CTBP1; -.
DR   GenomeRNAi; 1487; -.
DR   PRO; PR:Q13363; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000159692; -.
DR   CleanEx; HS_CTBP1; -.
DR   ExpressionAtlas; Q13363; baseline and differential.
DR   Genevisible; Q13363; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005667; C:transcription factor complex; IEA:Ensembl.
DR   GO; GO:0017053; C:transcriptional repressor complex; IDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0051287; F:NAD binding; ISS:UniProtKB.
DR   GO; GO:0016616; F:oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor; IEA:InterPro.
DR   GO; GO:0008022; F:protein C-terminus binding; TAS:ProtInc.
DR   GO; GO:0019904; F:protein domain specific binding; IDA:BHF-UCL.
DR   GO; GO:0070491; F:repressing transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0001106; F:RNA polymerase II transcription corepressor activity; IDA:BHF-UCL.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; TAS:ProtInc.
DR   GO; GO:0035067; P:negative regulation of histone acetylation; IMP:BHF-UCL.
DR   GO; GO:0090241; P:negative regulation of histone H4 acetylation; IMP:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:1903758; P:negative regulation of transcription from RNA polymerase II promoter by histone modification; IMP:BHF-UCL.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0031065; P:positive regulation of histone deacetylation; IMP:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0051726; P:regulation of cell cycle; IMP:BHF-UCL.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0019079; P:viral genome replication; TAS:ProtInc.
DR   GO; GO:0050872; P:white fat cell differentiation; ISS:UniProtKB.
DR   InterPro; IPR006139; D-isomer_2_OHA_DH_cat_dom.
DR   InterPro; IPR029753; D-isomer_DH_CS.
DR   InterPro; IPR029752; D-isomer_DH_CS1.
DR   InterPro; IPR006140; D-isomer_DH_NAD-bd.
DR   InterPro; IPR016040; NAD(P)-bd_dom.
DR   Pfam; PF00389; 2-Hacid_dh; 1.
DR   Pfam; PF02826; 2-Hacid_dh_C; 1.
DR   SUPFAM; SSF51735; SSF51735; 1.
DR   PROSITE; PS00065; D_2_HYDROXYACID_DH_1; 1.
DR   PROSITE; PS00671; D_2_HYDROXYACID_DH_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Alternative splicing;
KW   Complete proteome; Cytoplasm; Differentiation;
KW   Direct protein sequencing; Host-virus interaction; Isopeptide bond;
KW   NAD; Nucleus; Oxidoreductase; Phosphoprotein; Reference proteome;
KW   Repressor; Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN         1    440       C-terminal-binding protein 1.
FT                                /FTId=PRO_0000076041.
FT   NP_BIND     180    185       NAD. {ECO:0000250}.
FT   NP_BIND     237    243       NAD. {ECO:0000250}.
FT   NP_BIND     264    266       NAD. {ECO:0000250}.
FT   NP_BIND     315    318       NAD. {ECO:0000250}.
FT   REGION        1     70       Interaction with GLIS2 1. {ECO:0000250}.
FT   REGION      288    360       Interaction with GLIS2 2. {ECO:0000250}.
FT   ACT_SITE    266    266       {ECO:0000250}.
FT   ACT_SITE    295    295       {ECO:0000250}.
FT   ACT_SITE    315    315       Proton donor. {ECO:0000250}.
FT   BINDING     100    100       NAD. {ECO:0000250}.
FT   BINDING     204    204       NAD. {ECO:0000250}.
FT   BINDING     290    290       NAD. {ECO:0000250}.
FT   MOD_RES     300    300       Phosphoserine.
FT                                {ECO:0000244|PubMed:17525332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     422    422       Phosphoserine; by HIPK2.
FT                                {ECO:0000269|PubMed:14567915}.
FT   CROSSLNK    428    428       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000269|PubMed:12679040}.
FT   VAR_SEQ       1     13       MGSSHLLNKGLPL -> MS (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_043305.
FT   MUTAGEN     134    134       C->A: Strongly reduces E1A binding; when
FT                                associated with A-138; A-141 and A-150.
FT                                {ECO:0000269|PubMed:12419229}.
FT   MUTAGEN     138    138       N->A: Strongly reduces E1A binding; when
FT                                associated with A-134; A-141 and A-150.
FT                                {ECO:0000269|PubMed:12419229}.
FT   MUTAGEN     141    142       RR->AA: Strongly reduces E1A binding;
FT                                when associated with A-163 and A-171.
FT                                {ECO:0000269|PubMed:12419229}.
FT   MUTAGEN     141    141       R->A: Strongly reduces E1A binding; when
FT                                associated with A-134; A-138 and A-150.
FT                                {ECO:0000269|PubMed:12419229}.
FT   MUTAGEN     150    150       L->A: Strongly reduces E1A binding; when
FT                                associated with A-134; A-138 and A-141.
FT                                {ECO:0000269|PubMed:12419229}.
FT   MUTAGEN     163    163       R->A: Strongly reduces E1A binding; when
FT                                associated with A-141; A-142 and A-171.
FT                                {ECO:0000269|PubMed:12419229}.
FT   MUTAGEN     171    171       R->A: Strongly reduces E1A binding; when
FT                                associated with A-141; A-142 and A-163.
FT                                {ECO:0000269|PubMed:12419229}.
FT   MUTAGEN     181    181       G->V: Strongly reduces E1A binding; when
FT                                associated with V-183 and A-204.
FT                                {ECO:0000269|PubMed:12419229}.
FT   MUTAGEN     183    183       G->V: Strongly reduces E1A binding; when
FT                                associated with V-181 and A-204.
FT                                {ECO:0000269|PubMed:12419229}.
FT   MUTAGEN     204    204       D->A: Strongly reduces E1A binding; when
FT                                associated with V-181 and V-183.
FT                                {ECO:0000269|PubMed:12419229}.
FT   MUTAGEN     266    266       R->A: Strongly reduces E1A binding; when
FT                                associated with A-290; A-295 and A-315.
FT                                {ECO:0000269|PubMed:12419229}.
FT   MUTAGEN     290    290       D->A: Strongly reduces E1A binding; when
FT                                associated with A-266; A-295 and A-315.
FT                                {ECO:0000269|PubMed:12419229}.
FT   MUTAGEN     295    295       E->A: Strongly reduces E1A binding; when
FT                                associated with A-266; A-290 and A-315.
FT                                {ECO:0000269|PubMed:12419229}.
FT   MUTAGEN     315    315       H->A: Strongly reduces E1A binding; when
FT                                associated with A-266; A-290 and A-295.
FT                                {ECO:0000269|PubMed:12419229}.
FT   MUTAGEN     422    422       S->A: Abolishes phosphorylation by HIPK2
FT                                and prevents UV-induced clearance.
FT                                {ECO:0000269|PubMed:14567915}.
FT   STRAND       29     34       {ECO:0000244|PDB:1MX3}.
FT   TURN         39     41       {ECO:0000244|PDB:1MX3}.
FT   HELIX        42     45       {ECO:0000244|PDB:1MX3}.
FT   TURN         46     48       {ECO:0000244|PDB:1MX3}.
FT   STRAND       50     53       {ECO:0000244|PDB:1MX3}.
FT   HELIX        59     61       {ECO:0000244|PDB:1MX3}.
FT   HELIX        64     69       {ECO:0000244|PDB:1MX3}.
FT   STRAND       70     75       {ECO:0000244|PDB:1MX3}.
FT   STRAND       77     79       {ECO:0000244|PDB:1MX3}.
FT   HELIX        83     86       {ECO:0000244|PDB:1MX3}.
FT   STRAND       94    100       {ECO:0000244|PDB:1MX3}.
FT   HELIX       107    112       {ECO:0000244|PDB:1MX3}.
FT   STRAND      116    118       {ECO:0000244|PDB:1MX3}.
FT   TURN        121    124       {ECO:0000244|PDB:4U6S}.
FT   HELIX       125    141       {ECO:0000244|PDB:1MX3}.
FT   HELIX       143    151       {ECO:0000244|PDB:1MX3}.
FT   HELIX       159    165       {ECO:0000244|PDB:1MX3}.
FT   TURN        166    168       {ECO:0000244|PDB:1MX3}.
FT   STRAND      176    180       {ECO:0000244|PDB:1MX3}.
FT   HELIX       184    194       {ECO:0000244|PDB:1MX3}.
FT   TURN        195    197       {ECO:0000244|PDB:1MX3}.
FT   STRAND      199    203       {ECO:0000244|PDB:1MX3}.
FT   HELIX       211    215       {ECO:0000244|PDB:1MX3}.
FT   HELIX       223    229       {ECO:0000244|PDB:1MX3}.
FT   STRAND      231    235       {ECO:0000244|PDB:1MX3}.
FT   STRAND      246    248       {ECO:0000244|PDB:1MX3}.
FT   HELIX       249    252       {ECO:0000244|PDB:1MX3}.
FT   STRAND      259    263       {ECO:0000244|PDB:1MX3}.
FT   HELIX       267    269       {ECO:0000244|PDB:4U6S}.
FT   HELIX       272    280       {ECO:0000244|PDB:1MX3}.
FT   STRAND      283    290       {ECO:0000244|PDB:1MX3}.
FT   STRAND      293    296       {ECO:0000244|PDB:1MX3}.
FT   TURN        303    306       {ECO:0000244|PDB:1MX3}.
FT   STRAND      308    312       {ECO:0000244|PDB:1MX3}.
FT   HELIX       321    340       {ECO:0000244|PDB:1MX3}.
FT   TURN        343    346       {ECO:0000244|PDB:1MX3}.
FT   STRAND      348    350       {ECO:0000244|PDB:1MX3}.
SQ   SEQUENCE   440 AA;  47535 MW;  F071DD30B385603F CRC64;
     MGSSHLLNKG LPLGVRPPIM NGPLHPRPLV ALLDGRDCTV EMPILKDVAT VAFCDAQSTQ
     EIHEKVLNEA VGALMYHTIT LTREDLEKFK ALRIIVRIGS GFDNIDIKSA GDLGIAVCNV
     PAASVEETAD STLCHILNLY RRATWLHQAL REGTRVQSVE QIREVASGAA RIRGETLGII
     GLGRVGQAVA LRAKAFGFNV LFYDPYLSDG VERALGLQRV STLQDLLFHS DCVTLHCGLN
     EHNHHLINDF TVKQMRQGAF LVNTARGGLV DEKALAQALK EGRIRGAALD VHESEPFSFS
     QGPLKDAPNL ICTPHAAWYS EQASIEMREE AAREIRRAIT GRIPDSLKNC VNKDHLTAAT
     HWASMDPAVV HPELNGAAYR YPPGVVGVAP TGIPAAVEGI VPSAMSLSHG LPPVAHPPHA
     PSPGQTVKPE ADRDHASDQL
//
